D
DAAN Biotherapeutics
Dianvanio teputics is leading in the development of anti-diabetics and cell therapy for solid cancer
About DAAN Biotherapeutics
DAAN Biotherapeutics is a pioneering company in the field of cancer treatment, focusing on innovative therapies to combat solid tumors. The company specializes in research and development of cell therapies, antibodies, and small molecule inhibitors. DAAN Biotherapeutics primarily serves cancer patients, aiming to provide advanced treatment options where traditional therapies fall short. The company operates in the biopharmaceutical market, leveraging cutting-edge science to develop new immune cell therapies, particularly targeting lung cancer with T Cell Receptor (TCR) based natural killer cells. DAAN Biotherapeutics generates revenue through the development and commercialization of these advanced cancer treatments, collaborating with various partners and stakeholders in the healthcare sector.
Source: Dealroom company dataAt a glance
- Status
- Operational
- Open positions
- None listed
- Dealroom signal
- 18.7/100
- Business model
- Manufacturing
- Client focus
- B2B
- Links
- Website
News
Open roles
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| SERIES A✓Equity / VC | Jan 2024 | $19M | $77M | Stonebridge Ventures · Solidus Investment · Atinum Investment · Shinhan Capital | ↗ |
| SEED✓Equity / VC | Jan 2022 | $4.2M | $17M | Company K Partners | ↗ |
Growth signals
Latest recorded traffic for DAAN Biotherapeutics is 2.5K monthly website visits, up 31.6% over the last three months.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
DAAN Biotherapeutics in the Seoul ecosystem
The DAAN Biotherapeutics office with the hot startups, most funded companies and investors around it. Hover or tap a pin.
Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Seed1 investor entered at this stage
Company K Partners
Series A11 investors entered at this stage
Stonebridge Ventures
Solidus Investment
Atinum Investment- SCShinhan Capital
Solasta Ventures- DPDaily Partners
Paratus Investment
KB Investment
FuturePlay- TMTimefolio Asset Management
Heungkuk Asset Management
Other known investors1 additional known investor
Aju IB Investment
Source: Dealroom Talent Intelligence.
Global footprint
Market sentiment
An AI-synthesised read of the highest-engagement posts about DAAN Biotherapeutics on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See DAAN Biotherapeutics’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.







